Pulse Biosciences, Inc. (PLSE)
| Market Cap | 59.31M |
| Revenue (ttm) | 1.86M |
| Net Income (ttm) | -62.29M |
| Shares Out | 29.80M |
| EPS (ttm) | -2.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 175,790 |
| Open | 2.23 |
| Previous Close | 2.14 |
| Day's Range | 1.95 - 2.25 |
| 52-Week Range | 1.41 - 29.16 |
| Beta | 1.89 |
| Analysts | Buy |
| Price Target | 11.39 (+472.4%) |
| Earnings Date | May 11, 2022 |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 201...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PLSE stock is "Buy." The 12-month stock price forecast is 11.39, which is an increase of 472.36% from the latest price.
News
Pulse Biosciences, Inc. Announces Changes to its Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System Powered by Nano-P...
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 5.88% and 36.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulse Biosciences Reports First Quarter 2022 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, to...
Pulse Biosciences, Inc. Announces Commencement of Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced that it has commenced its previousl...
Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, an...
Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epi...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, to...
PLSE DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel ...
New York, New York--(Newsfile Corp. - April 18, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Jan...
Deadline Today: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contac...
Los Angeles, California--(Newsfile Corp. - April 18, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, In...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Bios...
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 18, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors ...
Deadline Monday Notice: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 t...
Los Angeles, California--(Newsfile Corp. - April 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, In...
PLSE Final Deadline: ROSEN, A Leading Law Firm, Encourages Pulse Biosciences, Inc. Investors with Losses Exceeding $1...
New York, New York--(Newsfile Corp. - April 15, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Jan...
PLSE DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel ...
NEW YORK , April 14, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 ...
Pulse Biosciences, Inc. Announces Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced that the Company's Board of Directo...
Deadline Monday Reminder: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000...
Los Angeles, California--(Newsfile Corp. - April 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, In...
Monday Deadline Notice: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 t...
Los Angeles, California--(Newsfile Corp. - April 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, In...
PLSE MONDAY DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors With Losses Ov...
New York, New York--(Newsfile Corp. - April 12, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Jan...
PLSE Investors Have Opportunity to Lead Pulse Biosciences, Inc. Securities Fraud Lawsuit
LOS ANGELES, April 12, 2022 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against P...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pulse Biosciences, Inc. - PLSE
NEW YORK , April 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised t...
PLSE APPROACHING DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Pulse Biosciences, Inc. Investors With Losses to Sec...
New York, New York--(Newsfile Corp. - April 8, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Janu...
ROSEN, Leading Investor Counsel, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important Apri...
New York, New York--(Newsfile Corp. - April 5, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Janu...
ROSEN, A LEADING LAW FIRM, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important April 18 D...
New York, New York--(Newsfile Corp. - April 3, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Janu...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors With Losses to Secure Counsel Before Imp...
NEW YORK--(BUSINESS WIRE)-- #Biosciences--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 ...
ROSEN, A TOP RANKED FIRM, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important April 18 De...
New York, New York--(Newsfile Corp. - April 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Janu...
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 22% and 6.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, to...